On this page
Two hormone-pathway signals do not establish a clinically useful combination.
CJC-1295 and ipamorelin can influence growth-hormone signalling through different receptors. Human studies show that each can move hormone biomarkers in specific research settings. They do not establish that the popular combination improves body composition, recovery, sleep, longevity or athletic performance.
| Question | CJC-1295 | Ipamorelin | What the comparison does not prove |
|---|---|---|---|
| Research class | Long-acting growth-hormone-releasing hormone analogue | Ghrelin-receptor agonist and growth-hormone secretagogue | Different receptors do not prove beneficial synergy |
| Direct human signal | Older studies measured GH and IGF-1 changes in healthy adults | Human pharmacology and a postoperative-ileus trial exist | Biomarker or disease-specific findings do not validate wellness claims |
| Regulatory signal | Named in TGA unapproved-peptide warnings and FDA safety material | Named in TGA advertising guidance and FDA compounding material | Research or compounding discussion is not approval |
| Sport | Named by WADA among growth-hormone-releasing factors | Named by WADA among growth-hormone secretagogues | A “research use” label does not change anti-doping rules |
What is the proposed combination?
CJC-1295 acts through the growth-hormone-releasing hormone receptor. Ipamorelin acts through the growth-hormone secretagogue receptor, also called the ghrelin receptor or GHSR1a. Both pathways can stimulate pituitary growth-hormone release, so online explanations often describe them as complementary.
That is a mechanism hypothesis. To establish a useful combination, research would need to test the exact substances together, in a defined population, against an appropriate comparator, with clinically meaningful outcomes and sufficiently long safety follow-up. Separate single-agent studies cannot supply those missing results.
How a plausible pathway becomes an unsupported claim
Two upstream receptors can affect one hormone axis.
2. Biomarker movementGH or IGF-1 concentrations may change.
Function, symptoms or disease outcomes must be measured directly.
4. Net benefitHarms, durability and relevance to the tested population must be included.
What do the CJC-1295 human studies show?
Small studies published in the mid-2000s evaluated a long-acting CJC-1295 construct in healthy adults. They reported prolonged pharmacodynamic effects on growth hormone and IGF-1 and examined whether growth-hormone pulsatility persisted. A separate analysis described changes in serum proteins associated with GH/IGF-1 activity.
These studies establish human biological activity for the studied long-acting construct. They were not trials of the current online CJC-1295/ipamorelin combination, did not establish anti-ageing benefit, and do not resolve long-term safety.
| Human evidence | Population and design | Measured result | Important limit |
|---|---|---|---|
| CJC-1295 pharmacology | Small ascending-dose studies in healthy adults | GH, IGF-1, pharmacokinetics and short-term tolerability | Biomarkers; not a therapeutic-outcome programme |
| CJC-1295 pulsatility study | Healthy volunteers after a single studied exposure | Characteristics of endogenous GH pulses | Does not establish chronic clinical benefit |
| Ipamorelin pharmacology | Dose-escalation study in healthy male volunteers | Concentration–response modelling for GH release | Short-term pharmacology, not efficacy |
| Ipamorelin postoperative ileus trial | Randomised, placebo-controlled phase 2 study after bowel resection | Disease-specific gastrointestinal outcomes and adverse events | Not an anti-ageing, recovery or body-composition study |
| Exact CJC-1295 + ipamorelin combination | No robust outcome programme identified in the reviewed primary sources | Not established | Cannot borrow proof from separate agents |
What does the ipamorelin evidence add?
Ipamorelin has human pharmacokinetic and pharmacodynamic data showing growth-hormone release under controlled experimental conditions. It was also tested as a ghrelin mimetic for postoperative ileus after bowel surgery. The published proof-of-concept trial did not turn ipamorelin into an approved general-purpose growth-hormone therapy, and its clinical setting cannot be translated into bodybuilding, recovery or longevity claims.
What safety concerns have regulators identified?
The FDA’s current compounding safety table states that CJC-1295 may present immunogenicity and peptide-impurity characterisation risks and notes serious adverse events including increased heart rate and a systemic vasodilatory reaction. The same source highlights aggregation, impurity and characterisation concerns for ipamorelin acetate, and says available safety information is insufficient for several injectable routes.
FDA advisory material also discusses serious events in the postoperative-ileus programme. These records justify caution; they should not be simplified into a claim that every event was caused by every formulation.
| Claim seen online | Best available interpretation | What is missing |
|---|---|---|
| “Two pathways create synergy” | Mechanistically plausible co-stimulation | Controlled combination outcomes and interaction safety |
| “Selective GH release means safer” | Selectivity is a pharmacology property | Long-term comparative safety in the claimed population |
| “IGF-1 increased, therefore recovery improved” | A biomarker moved | Direct functional outcome and net-benefit evidence |
| “No DAC is simply shorter CJC-1295” | Commercial naming is inconsistent | Exact sequence, modification, identity and validated composition |
| “Research use only makes supply lawful” | The TGA explicitly rejects that shortcut | Applicable Australian regulatory pathway and professional authority |
With DAC, without DAC and Modified GRF: why the names matter
The published long-acting CJC-1295 research concerns a drug-affinity-complex design intended to bind albumin. Online sellers often use “CJC-1295 no DAC” for shorter GHRH analogues, sometimes interchangeably with Modified GRF (1-29). Those labels do not by themselves prove the exact sequence or formulation. Read the dedicated CJC-1295 no-DAC terminology guide and the CJC-1295 with-DAC human-evidence profile before comparing claims.
Australian regulation and sport
The October 2026 Poisons Standard lists CJC-1295 (CAS No. 863288-34-0) and ipamorelin in Schedule 4 and in Appendix D, clause 5 (items 7 and 25, respectively). The named CJC-1295 entry does not, by itself, identify every product marketed as “no DAC” or Modified GRF. That classification controls availability and possession; it does not itself establish that a product is included in the ARTG for a promoted indication. The TGA’s September 2026 peptide guidance also states that a “research use only” disclaimer does not make supply lawful.
The 2026 WADA Prohibited List names CJC-1295 among growth-hormone-releasing factors and ipamorelin among growth-hormone secretagogues, prohibited at all times.
Frequently asked questions
Is CJC-1295 the same as ipamorelin?
No. CJC-1295 is a GHRH analogue; ipamorelin is a ghrelin-receptor agonist and growth-hormone secretagogue. They influence the same broader hormone axis through different upstream receptors.
Has the exact combination been proven in humans?
The reviewed primary sources contain separate human pharmacology for CJC-1295 and ipamorelin, plus a disease-specific ipamorelin trial. They do not establish broad clinical benefits for the popular combined product.
Does a GH or IGF-1 increase prove improved recovery?
No. Hormone concentrations are biomarkers. Recovery, function, body composition and safety require direct outcome measurement.
Is “CJC-1295 no DAC” a precise scientific name?
Not reliably. Commercial usage is inconsistent. The exact sequence, modification and analytical identity must be established rather than inferred from the label.
Are CJC-1295 and ipamorelin approved for anti-ageing?
The reviewed official sources do not establish an approved anti-ageing indication. Scheduling, experimental study and compounding discussion are not equivalent to ARTG or FDA approval.
Are athletes allowed to use them?
The 2026 WADA Prohibited List names both in categories prohibited at all times. Athletes should use official anti-doping resources for decisions affecting eligibility.
Primary sources
- Teichman et al.: CJC-1295 pharmacokinetics, GH and IGF-1 in healthy adults
- Ionescu and Frohman: GH pulsatility after CJC-1295
- CJC-1295 and serum markers of GH/IGF-1 activity
- Ipamorelin pharmacokinetic–pharmacodynamic modelling in human volunteers
- Randomised ipamorelin postoperative-ileus proof-of-concept trial
- FDA: bulk substances that may present significant safety risks
- TGA: responsibilities for unapproved peptide products
- Australian Poisons Standard, October 2026
- WADA 2026 Prohibited List
Scope: Evidence and regulatory information only. This page does not provide dosing, administration, sourcing or personal medical advice. No independent clinician reviewer is attributed to this update.
How to cite this article
CJC-1295 and Ipamorelin: Evidence, FDA Safety Flags and 2026 WADA Status. Elite Peps Australia. Published 15 September 2026; updated 22 October 2026. https://elitepepsaustralia.com/cjc-1295-ipamorelin-evidence-fda-safety-wada-2026/
Source checks: Consult the primary studies, trial records and regulator documents linked in this article for current evidence and status. Publication and update dates do not by themselves indicate an evidence review.